vs

Side-by-side financial comparison of GERON CORP (GERN) and Ibotta, Inc. (IBTA). Click either name above to swap in a different company.

Ibotta, Inc. is the larger business by last-quarter revenue ($88.5M vs $47.2M, roughly 1.9× GERON CORP). On growth, GERON CORP posted the faster year-over-year revenue change (67.1% vs -10.0%). Over the past eight quarters, GERON CORP's revenue compounded faster (1597.0% CAGR vs 3.7%).

Geron Corporation is a biotechnology company located in Foster City, California which specializes in developing and commercializing therapeutic products for cancer that inhibit telomerase.

Ibotta, Inc. is an American mobile technology company headquartered in Denver, Colorado. Founded in 2011, the company offers cash back rewards on various purchases through its Ibotta Performance Network and direct to consumer app. Ibotta partners with CPG brands and network publishers to provide these rewards. As of 2024, the company operates solely in the United States. The company's rewards-as-a-service offering, the Ibotta Performance Network, went live in 2022.

GERN vs IBTA — Head-to-Head

Bigger by revenue
IBTA
IBTA
1.9× larger
IBTA
$88.5M
$47.2M
GERN
Growing faster (revenue YoY)
GERN
GERN
+77.1% gap
GERN
67.1%
-10.0%
IBTA
Faster 2-yr revenue CAGR
GERN
GERN
Annualised
GERN
1597.0%
3.7%
IBTA

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
GERN
GERN
IBTA
IBTA
Revenue
$47.2M
$88.5M
Net Profit
$-18.4M
Gross Margin
78.7%
Operating Margin
-29.4%
-1.9%
Net Margin
-39.0%
Revenue YoY
67.1%
-10.0%
Net Profit YoY
30.3%
EPS (diluted)
$-0.03
$-0.03

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GERN
GERN
IBTA
IBTA
Q4 25
$88.5M
Q3 25
$47.2M
$83.3M
Q2 25
$49.0M
$86.0M
Q1 25
$39.6M
$84.6M
Q4 24
$98.4M
Q3 24
$28.3M
$98.6M
Q2 24
$882.0K
$87.9M
Q1 24
$304.0K
$82.3M
Net Profit
GERN
GERN
IBTA
IBTA
Q4 25
Q3 25
$-18.4M
$1.5M
Q2 25
$-16.4M
$2.5M
Q1 25
$-19.8M
$555.0K
Q4 24
Q3 24
$-26.4M
$17.2M
Q2 24
$-67.4M
$-34.0M
Q1 24
$-55.4M
$9.3M
Gross Margin
GERN
GERN
IBTA
IBTA
Q4 25
78.7%
Q3 25
79.4%
Q2 25
79.2%
Q1 25
79.8%
Q4 24
84.6%
Q3 24
87.7%
Q2 24
86.0%
Q1 24
87.2%
Operating Margin
GERN
GERN
IBTA
IBTA
Q4 25
-1.9%
Q3 25
-29.4%
2.8%
Q2 25
-25.4%
1.4%
Q1 25
-42.2%
-3.3%
Q4 24
13.2%
Q3 24
-99.8%
21.0%
Q2 24
-7860.9%
-24.6%
Q1 24
-18465.1%
19.3%
Net Margin
GERN
GERN
IBTA
IBTA
Q4 25
Q3 25
-39.0%
1.8%
Q2 25
-33.4%
2.9%
Q1 25
-50.1%
0.7%
Q4 24
Q3 24
-93.5%
17.5%
Q2 24
-7639.8%
-38.6%
Q1 24
-18220.4%
11.3%
EPS (diluted)
GERN
GERN
IBTA
IBTA
Q4 25
$-0.03
Q3 25
$-0.03
$0.05
Q2 25
$-0.02
$0.08
Q1 25
$-0.03
$0.02
Q4 24
$3.04
Q3 24
$-0.04
$0.51
Q2 24
$-0.10
$-1.32
Q1 24
$-0.09
$0.33

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GERN
GERN
IBTA
IBTA
Cash + ST InvestmentsLiquidity on hand
$78.1M
$186.6M
Total DebtLower is stronger
$0
Stockholders' EquityBook value
$248.7M
$287.7M
Total Assets
$567.4M
$525.9M
Debt / EquityLower = less leverage
0.00×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GERN
GERN
IBTA
IBTA
Q4 25
$186.6M
Q3 25
$78.1M
$223.3M
Q2 25
$77.7M
$250.5M
Q1 25
$83.7M
$297.1M
Q4 24
$349.3M
Q3 24
$60.3M
$341.3M
Q2 24
$116.9M
$317.9M
Q1 24
$189.8M
$79.5M
Total Debt
GERN
GERN
IBTA
IBTA
Q4 25
$0
Q3 25
Q2 25
Q1 25
Q4 24
$0
Q3 24
$0
Q2 24
$0
Q1 24
$65.3M
Stockholders' Equity
GERN
GERN
IBTA
IBTA
Q4 25
$287.7M
Q3 25
$248.7M
$329.6M
Q2 25
$259.5M
$354.1M
Q1 25
$268.2M
$401.3M
Q4 24
$457.3M
Q3 24
$292.3M
$378.0M
Q2 24
$306.7M
$359.7M
Q1 24
$344.9M
$44.1M
Total Assets
GERN
GERN
IBTA
IBTA
Q4 25
$525.9M
Q3 25
$567.4M
$569.4M
Q2 25
$555.2M
$600.8M
Q1 25
$562.5M
$639.3M
Q4 24
$678.4M
Q3 24
$444.9M
$598.3M
Q2 24
$449.4M
$556.0M
Q1 24
$482.1M
$322.1M
Debt / Equity
GERN
GERN
IBTA
IBTA
Q4 25
0.00×
Q3 25
Q2 25
Q1 25
Q4 24
0.00×
Q3 24
0.00×
Q2 24
0.00×
Q1 24
1.48×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GERN
GERN
IBTA
IBTA
Operating Cash FlowLast quarter
$-13.6M
$27.8M
Free Cash FlowOCF − Capex
$20.3M
FCF MarginFCF / Revenue
22.9%
Capex IntensityCapex / Revenue
8.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$75.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GERN
GERN
IBTA
IBTA
Q4 25
$27.8M
Q3 25
$-13.6M
$21.8M
Q2 25
$-27.4M
$25.9M
Q1 25
$-48.0M
$19.9M
Q4 24
$22.0M
Q3 24
$-58.9M
$39.5M
Q2 24
$-53.5M
$35.0M
Q1 24
$-62.3M
$19.4M
Free Cash Flow
GERN
GERN
IBTA
IBTA
Q4 25
$20.3M
Q3 25
$14.5M
Q2 25
$22.2M
Q1 25
$18.0M
Q4 24
$21.8M
Q3 24
$39.2M
Q2 24
$-53.7M
$34.8M
Q1 24
$-62.9M
$19.2M
FCF Margin
GERN
GERN
IBTA
IBTA
Q4 25
22.9%
Q3 25
17.4%
Q2 25
25.8%
Q1 25
21.2%
Q4 24
22.1%
Q3 24
39.8%
Q2 24
-6086.6%
39.6%
Q1 24
-20680.3%
23.3%
Capex Intensity
GERN
GERN
IBTA
IBTA
Q4 25
8.5%
Q3 25
8.7%
Q2 25
4.2%
Q1 25
2.2%
Q4 24
0.2%
Q3 24
0.0%
0.3%
Q2 24
23.4%
0.2%
Q1 24
202.3%
0.2%
Cash Conversion
GERN
GERN
IBTA
IBTA
Q4 25
Q3 25
14.19×
Q2 25
10.38×
Q1 25
35.78×
Q4 24
Q3 24
2.29×
Q2 24
Q1 24
2.08×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

GERN
GERN

Segment breakdown not available.

IBTA
IBTA

Redemption Revenue$78.5M89%
Ad Other Revenue$10.0M11%
Breakage$2.1M2%

Related Comparisons